3.02
+1.34%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Shanghai Hile Bio-Technology Co
Its shares trade on Shanghai under the ticker 603718.SS. It has been listed since 15 May 2015. In the fiscal year to 31 December 2025, it reported revenue of CN¥187.9m and a net loss of CN¥311.4m. At that date it held total assets of CN¥1.13bn and shareholders' equity of CN¥882.0m.
Shanghai Hile Bio-Technology Co., Ltd. engages in the manufacture and sale of veterinary vaccine and inactivated vaccine. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2015-05-15. The Company’s products mainly include escherichia coli (K88 and K99) gene modified vaccines for piglets, inactivated; porcine reproductive and respiratory syndrome vaccines, live and swine infectious atrophic rhinitis vaccines, inactivated; newcastle disease mild vaccines, living; newcastle disease, infectious bronchitis, egg drop syndrome’76 vaccines, inactivated and infectious bronchitis vaccines, living, among others. The firm distributes its products mainly in China.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 15 May 2015
- Employees
- 491
- Website
- hile-bio.com ↗
Leadership
Pay as last reported
- Ms. Qun LinFinance Director, Director, since 2020CN¥344,700
- Mr. Benyi HanGeneral Manager, Director, since 2023
- Ms. Dongchan PuDeputy General Manager, Secretary of the BoardCN¥405,000
- Mr. Xiao ChenDeputy General Manager, Director, since 2023CN¥585,000
- Mr. Xiaoqiang XiangDeputy General Manager
- Ms. Yue ZhangDirectorCN¥317,200
- Ms. Jun CaoIndependent Director
- Mr. Yan GuIndependent DirectorCN¥15,000
- Mr. Tian Min LiuIndependent DirectorCN¥35,000
- Mr. Junqiang WangIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Shanghai Hile Bio-Technology Co Ltd manufactures veterinary vaccines in Shanghai with 491 employees.
- The company produces gene modified vaccines for piglets including K88 and K99 strains.
- Shanghai Hile distributes inactivated and live vaccines for porcine reproductive and respiratory syndrome in China.
Weaknesses
- Shanghai Hile Bio-Technology Co Ltd has no international distribution outside China.
- The company's product range is limited to veterinary vaccines without human applications.
- Shanghai Hile's IPO date was 15 May 2015, indicating limited market history.
Opportunities
- Shanghai Hile can expand into new veterinary vaccine segments within China's growing market.
- The company may develop new vaccines for emerging animal diseases in China.
- Shanghai Hile could leverage its 491 employees to increase production capacity.
Threats
- Shanghai Hile faces competition from domestic veterinary vaccine manufacturers in China.
- The company's reliance on China's market exposes it to regional economic fluctuations.
- Shanghai Hile's product portfolio lacks diversity beyond veterinary vaccines.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.